5 completed, 1 recruiting, 1 terminated, 1 unknown. 3 Not applicable, 3 Phase 3, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Fasciculation: new trials by email Literature Review of Fasciculation trials Research Report on Fasciculation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Evolution of Lumbar Spine Movement Fluidity Using Xsens Inertial Sensors in Subjects With Chronic Low Back Pain Before and After Rehabilitation X-sens sensor - Low Back Pain | Not applicable | Recruiting | University Hospital, Montpellier | 25 | 2026-02-23 | 2026-06-12 |
| Median Effective Dose of Cisatracurium for the Prevention of Fasciculation Caused by the Injection of Succinylcholine Cisatracurium - Fasciculation, Succinylcholine | Not applicable | Unknown | Yangzhou University | 90 | 2023-02-01 | 2023-03-09 |
| The Effect of Pretreatment With Roc on Succinylcholine Myalgias non-pretreated Succinylcholine, succinylcholine 1 minute after rocuronium pretreatment, succinylcholine 2 minutes following rocuronium pretreatment - Myalgia | Phase 3 | Completed | Indiana University | 300 | 2020-10-02 | 2024-08-21 |
| Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS FLX-787-ODT - Amyotrophic Lateral Sclerosis, Fasciculation | Phase 1 / Phase 2 | Terminated | Flex Pharma, Inc. | 3 | 2018-04-05 | 2018-08-29 |
| Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS FLX-787-ODT (orally disintigrating tablet) - Amyotrophic Lateral Sclerosis, Fasciculation | Phase 1 / Phase 2 | Withdrawn | Flex Pharma, Inc. | 2017-11-01 | 2018-01-23 | |
| Effects of Cisatracurium on Sccinylcholine-induced Fasciculations Cisatracurium - Fasciculations | Phase 3 | Completed | Zhuan Zhang | 87 | 2015-07-01 | 2015-10-12 |
| Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Completed | Universidad Católica San Antonio de Murcia | 60 | 2013-09-01 | 2015-07-24 | |
| Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia Cisatracurium - Fasciculation | Phase 3 | Completed | Yangzhou No.1 People's Hospital | 90 | 2013-03-01 | 2015-06-25 |
| Muscle Relaxation for Short Procedures Succinylcholine, Rocuronium/Sugammadex, Rocuronium - Intubating Conditions, Fasciculations | Not applicable | Completed | Dr. Horst Schmidt Klinik GmbH | 105 | 2011-10-01 | 2013-07-18 |
Amyotrophic Lateral Sclerosis (3) · Myalgia (2) · Low Back Pain (1) · Neuromuscular Diseases (1) · Patient Satisfaction (1) · Pharyngitis (1)
Nervous System Diseases (9) · Neurologic Manifestations (9) · Neuromuscular Manifestations (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Neuromuscular Diseases (4) · Central Nervous System Diseases (3) · Metabolic Diseases (3) · Motor Neuron Disease (3) · Neurodegenerative Diseases (3) · Nutritional and Metabolic Diseases (3) · Pain (3) · Proteostasis Deficiencies (3) · Spinal Cord Diseases (3) · TDP-43 Proteinopathies (3)
cisatracurium (3) · Succinylcholine (2) · Control Groups (1) · Rocuronium (1) · Sugammadex (1)
Flex Pharma, Inc. (2) · Dr. Horst Schmidt Klinik GmbH (1) · Indiana University (1) · Universidad Católica San Antonio de Murcia (1) · University Hospital, Montpellier (1) · Yangzhou No.1 People's Hospital (1) · Yangzhou University (1) · Zhuan Zhang (1)
United States (3) · China (1) · France (1) · Germany (1) · Spain (1)
Grietje Beck, Prof (1) · Leighan Bye, MD (1) · Xin-nong Liu, Professor (1)
PMID 17964067, PMID 18506712, PMID 19486136, PMID 20392981, PMID 20810308, PMID 22239880, PMID 22244867